CONSUN PHARMA (01681) has been added to the Hang Seng Composite Index, according to the quarterly review results of the Hang Seng Index Series announced by Hang Seng Indexes Company on February 13, covering the period up to December 31, 2025. The changes will take effect after the market close on Friday, March 6, 2026, and will be implemented starting Monday, March 9, 2026. Following this adjustment, the Shanghai and Shenzhen stock exchanges are expected to update the list of eligible stocks for Southbound Stock Connect trading.

A research report from CICC indicated that CONSUN PHARMA is likely to be included in the Southbound Stock Connect program, as it meets a range of criteria including market capitalization, liquidity, and listing duration.

In a previous announcement, CONSUN PHARMA disclosed that its board passed a resolution on June 13, 2025, to execute a share repurchase plan, allowing the company to buy back shares on the open market as appropriate, with a total cap of HK$200 million. Subsequently, on January 29, 2026, the board approved an additional share repurchase plan, increasing the total repurchase amount by up to HK$100 million, bringing the combined maximum repurchase value to HK$300 million.

The share repurchase initiative will remain in effect from the announcement date until the conclusion of the company’s next annual general meeting or until the board’s repurchase authorization is revoked or amended by shareholders.